Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects

Pakistan Journal of Pharmaceutical Sciences

Volumn 22, Issue 1, 2009, Pages 1-7

  Khan, Muhammad Khalid ^a   Khan, Muhammad Farid ^a  

^a GOMAL UNIVERSITY   (Pakistan)

Author keywords

Bioassay of ciprofloxacin test and reference; Bioequivalence; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN; DRUG METABOLITE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROCOCCUS FAECALIS; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CHEMISTRY; CROSSOVER PROCEDURE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HALF LIFE TIME; MICROBIOLOGICAL EXAMINATION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; TABLET;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; CROSS-OVER STUDIES; ENTEROCOCCUS FAECALIS; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 61949102048     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Abdallah RM, Alam SM, Awaad FM, Dham R, El-Kersh A, El-Laithy A, Shalby MH, Shihabeddin M, El-Walily AF, Yacout M and Zaman Q (2002). Bioequivalence of two brands of ciprofloxacin 750 mg tablets (Sarf andCiprobay) in healthy human volunteers. Drug Dev Ind. Pharm., 28(4): 423-429.
2. Aliabadi FS and Lees P (1997). Pharmacodynamic and Pharmacokinetic inter relationship of antibacterial drugs. J. Vet Phramacol. Therap. 20(Suppl. 1): 14-17.
3. Anadon A, Maninez-Larranaga MR, Diaz J, Bringas P, Martmez MA, Pernandez-cruz ML, Pernandez MC and Pernandez R (1995). Pharmacokieties and residues of enrofloxacin in chickens. Am. J. Vet. Res., 56: 501-506.
4. Arret B, Johnson DP and Kirshbaum (1971). Outline of details for microbiological assays of antibiotics. Second revision. J. Pharm. Sci., 60: 1689-1694.
5. th Ed.., Iowa State University Press Ames, pp.829-830.
6. Bottner A, Schmid P and Hume R (1995). In vitro efficacy of cefquinone (INN) and other anti-infective drugs against bovine bacterial isolates from Belgium, France, Germany, The Netherlands, & the United Kingdom. J. Vet. Med. B 42: 377-383.
7. Breilh D, Saux MC, Maire P, Vergnaud JM and Jelliffe RW (2001). Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations. Comput. Biol. Med., 31(3): 147-155. (Pubitemid 32149921)
8. Brown SA (1996). Fluoroquinolones in animal Health. J. Vet. Phaaarmacol. Therap., 19: 1-14.
9. Catchpole C., Andrews JM., Woodcock J and Wise R (1994). The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J. Antimicrob. Chemother., 33(1): 103-110. (Pubitemid 24043845)
10. Definitions, Bioavailability and Bioequivalence Requirements, (1991) 21 CFR, 320.1
11. Dowling PM, Wilson RC, Tyler JW and Duran SH (1995). Pharmacokinetics of Ciprofloxacin in ponies J. Vet. Pharmacol. & Therap., 18: 7-12
12. Drusano GL, Johnson DE, Rosen M and Standiford HC (1993). Pharmacodynamics of a fluoroquinolones antimicrobial agent in a neutropenic rat model of Pesudomonas sepsis. Antimicrob. Agents Chemotherap. 37: 448-490. (Pubitemid 23072592)
13. Escobar Y and Hoyo-Vaditlo C (2003). Pharmacokinetics of ciprofloxacin in healthy Mexican volunteers. Arzneimitteiforschung; 53(9): 664-667.
14. Garcia Ovando H, Errecaldc C, Prieto G, Ludcrs C, Puelles I, Berccochea C and Fernandez W (1996a). Pharmacokinetics of enrofloxacin in calves. Atrchievos de Medicina V'eterinaria, 28: 107-111.
15. Garrelts JC, Jost G, Kowalsky SF, Krol GJ and Lettieri JT (1996). Ciprofloxacin Pharmacokinetic: In burn patients. Antimicrobial Agents & Chemotherapy. 40(5): 1153-1156.
16. Hoffken G, Lode H, Printing C, Borner K, Kocppe P (1985). Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob. Agents Chemother., 27(3): 375-379. (Pubitemid 15144703)
17. Hu C, Kneusei R and Barnas G (2003). Online Calculator. http://www.intmed.mcw.edu/clinicalc/ body. hlml.
18. LeBel M (1988). Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials and adverse reactions. Pharmacotherapy, 8(1): 3-33.
19. Lubasch A, Keller I, Borner K, Koeppe P and Lode H (2000). Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother., 44(10): 2600-2603. (Pubitemid 30737669)
20. Maya MT, Goncalves NJ, Silva NE, Filipe AE and Morais JA (2003). Bioequivalence evaluation of three different oral formulations of ciprofloxacin in healthy volunteers. Eur. J. Drug Metab. Pharmacokinet., 28(2): 129-136.
21. Nightinagle CH, Grant EM and Quintiliani R (2000). Pharmacodynamics and Pharmacokinetics of levofloxacin. Chemotherapy, 46(Suppl. 1): 6-14.
22. Nouws JFM, Mevius DJ, Vree TB, Baars AM and Laureensen J (1988). Pharmacokinetics, renal clearance and metabolism of Ciprofloxacin following intravenous and oral administration to calves and pigs. Vet. Quarterly, 10: 156-163.
23. Owens JR, Patel KB, Anevicius MA, Quintiliani R, Nightingale CH and Nicolau DP (1997). Oral Bioavailability and Pharmacokinetics of Ciprofloxacin in patients with Aids. Antimicrobial Agents and Chemotherapy, 4(7): 1508-1511. (Pubitemid 27289677)
24. Rao GS, Ramcsh S, Ahmad AH, Tripathi HC, Shrama LD and Malik JK (2002). Disposilion kinetics of enrofloxacin and ciprofloxacin following intravenous administration of enrofloxacin in goats. Small Ruminant Research, 44: 9-15.
25. Seth SD, Beotra A and Seth S (1995). Comparative bioavailability of two brands of .5 7 Ciprofloxacin. J. Assoc. Physicians India, 43(5): 327-330.
26. Thomas M and File JR (2001). Infectious diseases treatment updates. Fluoroquinolones Clin. Infect. Dis., 15: 726-735.
27. Xia W, Gyrd-Hansen N and Nielsen P (1983). Comparison of pharmacokmetic parameters for two oxyieiraitcycinic preparations in pigs. J. Vet. Pharcol. Therap., 6(2): 113-120.
28. Zeiler HJ and Grohe K (1984). The in vitro and in vivo activity of ciprofloxacin. Eur. J. Clin. Microbiol., 3(4): 339-343.